AZN
AstraZeneca PLC
NYSE · Healthcare · Drug Manufacturers - General · GB
$188.47
+2.50%Year over year
Reported trailing growth
- Revenue
- +7.0%
- EBITDA
- +18.6%
- EBIT
- +14.9%
- EPS
- -20.4%
- Free cash flow
- -2.6%
- Operating cash flow
- -11.9%
Forward estimates
Based on analyst estimates
- Revenue
- +6.2%
- EBITDA
- +49.2%
- EPS
- +51.9%
Three-year CAGR
- Revenue
- +9.8%
- EBITDA
- +29.7%
- EBIT
- +54.1%
- Net income
- +46.1%
- EPS
- +46.0%
- Free cash flow
- +6.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026